ZIA BC 011848 (ZIA) | |||
---|---|---|---|
Title | Preclinical Modelling and Therapeutic Development for Other Cancer Indications | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Sharan, Shyam | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $112,660 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Childhood Cancers (30.0%) |
Kidney Disease (40.0%) Nervous System (60.0%) Neuroblastoma (30.0%) Sarcoma (30.0%) Urinary System (40.0%) Wilm's Tumor (5.0%) Kidney Cancer (40.0%) |
||
Research Type | |||
Cancer Progression & Metastasis Systemic Therapies - Discovery and Development |
|||
Abstract | |||
The following joint projects co-led by CCR Investigators are presently in different stage of completion at CAPR: - with Dr. Michele Yohe, tolerance and efficacy assessment of dual BRD4/PI3K inhibitors +/- Histone Deacetylase (HDAC) inhibitors in PDX models established from RAS driven pediatric solid tumors; - CAPR work is ongoing with Dr. Carol Thiele and Dr. Jack Shern to test a BET domain inhibitor alone or in combination with a topoisomerase I inhibitor in Patient Derived Xenografts (PDX) of pediatric rhabdomyosarcoma and neuroblastoma; - a collaboration with Dr. Laura Schmidt aims at the development and validation of renal carcinoma models based on orthotopic implantation of kidney tumors that appear in mice harboring the PRCC-TFE3 transgene, and evaluation of latency and penetrance of tumors. |